Literature DB >> 23403405

Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia.

Jian Q Feng1, Erica L Clinkenbeard, Baozhi Yuan, Kenneth E White, Marc K Drezner.   

Abstract

Although recent studies have established that osteocytes function as secretory cells that regulate phosphate metabolism, the biomolecular mechanism(s) underlying these effects remain incompletely defined. However, investigations focusing on the pathogenesis of X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), and autosomal recessive hypophosphatemic rickets (ARHR), heritable disorders characterized by abnormal renal phosphate wasting and bone mineralization, have clearly implicated FGF23 as a central factor in osteocytes underlying renal phosphate wasting, documented new molecular pathways regulating FGF23 production, and revealed complementary abnormalities in osteocytes that regulate bone mineralization. The seminal observations leading to these discoveries were the following: 1) mutations in FGF23 cause ADHR by limiting cleavage of the bioactive intact molecule, at a subtilisin-like protein convertase (SPC) site, resulting in increased circulating FGF23 levels and hypophosphatemia; 2) mutations in DMP1 cause ARHR, not only by increasing serum FGF23, albeit by enhanced production and not limited cleavage, but also by limiting production of the active DMP1 component, the C-terminal fragment, resulting in dysregulated production of DKK1 and β-catenin, which contributes to impaired bone mineralization; and 3) mutations in PHEX cause XLH both by altering FGF23 proteolysis and production and causing dysregulated production of DKK1 and β-catenin, similar to abnormalities in ADHR and ARHR, but secondary to different central pathophysiological events. These discoveries indicate that ADHR, XLH, and ARHR represent three related heritable hypophosphatemic diseases that arise from mutations in, or dysregulation of, a single common gene product, FGF23 and, in ARHR and XLH, complimentary DMP1 and PHEX directed events that contribute to abnormal bone mineralization.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403405      PMCID: PMC3672228          DOI: 10.1016/j.bone.2013.01.046

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  48 in total

1.  Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen.

Authors:  S S Molloy; P A Bresnahan; S H Leppla; K R Klimpel; G Thomas
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

2.  Familial hypophosphatemic rickets showing autosomal dominant inheritance.

Authors:  J W Bianchine; A A Stambler; H E Harrison
Journal:  Birth Defects Orig Artic Ser       Date:  1971-05

3.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

Authors:  K E White; G Carn; B Lorenz-Depiereux; A Benet-Pages; T M Strom; M J Econs
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

4.  Growth disturbance in hereditary hypophosphatemia.

Authors:  H E Harrison; H C Harrison; F Lifshitz; A D Johnson
Journal:  Am J Dis Child       Date:  1966-10

5.  Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect.

Authors:  T Nesbitt; T M Coffman; R Griffiths; M K Drezner
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

6.  FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

Authors:  Takashi Shimada; Itaru Urakawa; Yuji Yamazaki; Hisashi Hasegawa; Rieko Hino; Takashi Yoneya; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Biochem Biophys Res Commun       Date:  2004-02-06       Impact factor: 3.575

7.  Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

Authors:  Takashi Shimada; Takanori Muto; Itaru Urakawa; Takashi Yoneya; Yuji Yamazaki; Katsuya Okawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

8.  FGF23 is processed by proprotein convertases but not by PHEX.

Authors:  Anna Benet-Pagès; Bettina Lorenz-Depiereux; Hans Zischka; Kenneth E White; Michael J Econs; Tim M Strom
Journal:  Bone       Date:  2004-08       Impact factor: 4.398

9.  Calcification of entheses associated with X-linked hypophosphatemic osteomalacia.

Authors:  R P Polisson; S Martinez; M Khoury; R M Harrell; K W Lyles; N Friedman; J M Harrelson; E Reisner; M K Drezner
Journal:  N Engl J Med       Date:  1985-07-04       Impact factor: 91.245

10.  Deletion of dentin matrix protein-1 leads to a partial failure of maturation of predentin into dentin, hypomineralization, and expanded cavities of pulp and root canal during postnatal tooth development.

Authors:  Ling Ye; Mary MacDougall; Shubin Zhang; Yixia Xie; Jianghong Zhang; Zubing Li; Yongbo Lu; Yuji Mishina; Jian Q Feng
Journal:  J Biol Chem       Date:  2004-02-13       Impact factor: 5.157

View more
  36 in total

Review 1.  Role of αKlotho and FGF23 in regulation of type II Na-dependent phosphate co-transporters.

Authors:  Ming Chang Hu; Mingjun Shi; Orson W Moe
Journal:  Pflugers Arch       Date:  2018-12-01       Impact factor: 3.657

Review 2.  Review of the dental implications of X-linked hypophosphataemic rickets (XLHR).

Authors:  Martin M I Sabandal; Peter Robotta; Sebastian Bürklein; Edgar Schäfer
Journal:  Clin Oral Investig       Date:  2015-02-13       Impact factor: 3.573

Review 3.  Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?

Authors:  R Sapir-Koren; G Livshits
Journal:  Osteoporos Int       Date:  2014-07-17       Impact factor: 4.507

4.  Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1(Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23.

Authors:  Yinshi Ren; Xianglong Han; Yan Jing; Baozhi Yuan; Huazhu Ke; Min Liu; Jian Q Feng
Journal:  Matrix Biol       Date:  2015-12-22       Impact factor: 11.583

5.  Loss of PiT-2 results in abnormal bone development and decreased bone mineral density and length in mice.

Authors:  Shunsuke Yamada; Mary C Wallingford; Suhaib Borgeia; Timothy C Cox; Cecilia M Giachelli
Journal:  Biochem Biophys Res Commun       Date:  2017-11-11       Impact factor: 3.575

Review 6.  Osteocytic signalling pathways as therapeutic targets for bone fragility.

Authors:  Lilian I Plotkin; Teresita Bellido
Journal:  Nat Rev Endocrinol       Date:  2016-05-27       Impact factor: 43.330

7.  Novel approaches for two and three dimensional multiplexed imaging of osteocytes.

Authors:  Suzan A Kamel-ElSayed; LeAnn M Tiede-Lewis; Yongbo Lu; Patricia A Veno; Sarah L Dallas
Journal:  Bone       Date:  2015-03-17       Impact factor: 4.398

Review 8.  A unified model for bone-renal mineral and energy metabolism.

Authors:  Peter S Rowe
Journal:  Curr Opin Pharmacol       Date:  2015-04-13       Impact factor: 5.547

9.  Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes.

Authors:  Heike Weidner; Ulrike Baschant; Franziska Lademann; Maria G Ledesma Colunga; Ekaterina Balaian; Christine Hofbauer; Barbara M Misof; Paul Roschger; Stéphane Blouin; William G Richards; Uwe Platzbecker; Lorenz C Hofbauer; Martina Rauner
Journal:  JCI Insight       Date:  2020-08-06

Review 10.  Aerobic glycolysis in osteoblasts.

Authors:  Emel Esen; Fanxin Long
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.